Crossmark

Repairing Peri-Anal Fistulas with regenerative cell therapeutics: study protocol for a double-blinded randomized controlled phase I–II trial from Denmark (REP-PAF)

Crossref DOI link: https://doi.org/10.1186/s13063-026-09565-y

Published Online: 2026-03-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sørensen, Karam Matlub https://orcid.org/0000-0002-3330-8525
Jensen, Charlotte Harken

Möller, Sören

Qvist, Niels

Andersen, Ditte Caroline

Sørensen, Jens Ahm
Funding

Funding for this research was provided by:

Novo Nordisk Fonden (NNF21OC0071847)

Novo Nordisk Fonden (NNF19OC0055353)

University of Southern Denmark
License Information

Text and Data Mining valid from 2026-03-04

Version of Record valid from 2026-03-19
More Information

Article History

Received: 7 October 2025

Accepted: 9 February 2026

First Online: 4 March 2026

Declarations

:

: The trial is registered and approved by the EMA (clinical and ethical). Trial identifier in CTIS is as follows: EU CT 2022-502659-73-01. Registered on 18 November 2023.URL: Search for clinical trials—EMA.

: Not applicable. No personal data will be published.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below